Biomarkers in rheumatology, Now and in the future

Rheumatology

Volumn 51, Issue 3, 2012, Pages 423-433

  Gibson, David S ^a,b   Rooney, Madeleine E ^a   Finnegan, Sorcha ^a   Qiu, Ji ^c   Thompson, David C ^d   Labaer, Joshua ^c   Pennington, Stephen R ^e   Duncan, Mark W ^b,f  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

^d University of Colorado Denver Anschutz Medical Campus   (United States)

^e UNIVERSITY COLLEGE DUBLIN   (Ireland)

^f Obesity Research Center   (Saudi Arabia)

Author keywords

Arthritis; Biomarker validation; Mass spectrometry; Protein microarray; Proteomics; Targeted analysis; Validation; Verification

Indexed keywords

ANTINUCLEAR ANTIBODY; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATININE; DOUBLE STRANDED DNA ANTIBODY; HLA B27 ANTIGEN; HLA DR4 ANTIGEN; HLA DRB1 ANTIGEN; PROTEIN VARIANT; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR INHIBITOR;

ANKYLOSING SPONDYLITIS; CLINICAL PRACTICE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROSPRAY MASS SPECTROMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; GLYCOSYLATION; HEALTH CARE DELIVERY; HUMAN; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; POINT OF CARE TESTING; PRIORITY JOURNAL; PROTEIN MICROARRAY; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEOMICS; QUADRUPOLE MASS SPECTROMETRY; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; TWO DIMENSIONAL GEL ELECTROPHORESIS;

BIOLOGICAL MARKERS; HUMANS; PROTEOMICS; RHEUMATOLOGY;

EID: 84857565407     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker358     Document Type: Review

References (80)

1. Anders HJ, Rihl M, Vielhauer V, Schattenkirchner M. Assessment of renal function in rheumatoid arthritis: validity of a new prediction method. J Clin Rheumatol 2002;8:130-3.
2. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111:1805-12.
3. Wiik AS. Anti-nuclear autoantibodies: clinical utility for diagnosis, prognosis, monitoring, and planning of treatment strategy in systemic immunoinflammatory diseases. Scand J Rheumatol 2005;34:260-8.
4. Chen PP, Robbins DL, Jirik FR et al. Isolation and characterization of a light chain variable region gene for human rheumatoid factors. J Exp Med 1987;166:1900-5.
5. Nakamura RM. Progress in the use of biochemical and biological markers for evaluation of rheumatoid arthritis. J Clin Lab Anal 2000;14:305-13.
6. Nielen MM, van Schaardenburg D, Reesink HW et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6.
7. Meyer O, Labarre C, Dougados M et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003;62:120-6.
8. Kavanaugh AF, Solomon DH American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests. Arthritis Rheum 2002;47:546-55.
9. van der Horst-Bruinsma IE, Visser H, Hazes JM et al. HLA-DQ-associated predisposition to and dominant HLA-DR-associated protection against rheumatoid arthritis. Hum Immunol 1999;60:152-8.
10. Wagner U, Kaltenhauser S, Sauer H et al. HLA markers and prediction of clinical course and outcome in rheumatoid arthritis. Arthritis Rheum 1997;40:341-51.
11. Vencovsky J, Machacek S, Sedova L et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003;62: 427-30.
12. Nishimura K, Sugiyama D, Kogata Y et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007;146:797-808.
13. van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP antibody, a marker for the early detection of rheumatoid arthritis. Ann N Y Acad Sci 2008;1143:268-85.
14. Lindqvist E, Eberhardt K, Bendtzen K et al. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005;64:196-201.
15. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 2004;63:1085-9.
16. Renger F, Bang H, Feist E et al. Immediate determination of ACPA and rheumatoid factor: a novel point of care test for detection of anti-MCV antibodies and rheumatoid factor using a lateral-flow immunoassay. Arthritis Res Ther 2010;12:R120.
17. Inanc N, Dalkilic E, Kamali S et al. Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol 2007;26:17-23.
18. Brunner J, Sitzmann FC. The diagnostic value of anti-cyclic citrullinated peptide (CCP) antibodies in children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2006;24:449-51.
19. Clifford BD, Donahue D, Smith L et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995;21: 613-9.
20. Hodson ME, Turner-Warwick M. Autoantibodies in patients with chronic bronchitis. Br J Dis Chest 1976;70: 83-8.
21. Isenberg DA, Shoenfeld Y, Walport M et al. Detection of cross-reactive anti-DNA antibody idiotypes in the serum of systemic lupus erythematosus patients and of their relatives. Arthritis Rheum 1985;28:999-1007.
22. Saurenmann RK, Levin AV, Feldman BM et al. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study. Arthritis Rheum 2007; 56:647-57.
23. Schlosstein L, Terasaki PI, Bluestone R et al. High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med 1973;288:704-6.
24. Brewerton DA, Hart FD, Nicholls A et al. Ankylosing spondylitis and HL-A 27. Lancet 1973;1:904-7.
25. Caffrey MF, James DC. Human lymphocyte antigen association in ankylosing spondylitis. Nature 1973;242: 121.
26. Wells GA, Boers M, Shea B et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 2005;32:2016-24.
27. Alonso-Ruiz A, Pijoan JI, Ansuategui E et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 2008;9:52.
28. Bongartz T, Sutton AJ, Sweeting MJ et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
29. Gygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 1999;19:1720-30.
30. Mann M, Jensen ON. Proteomic analysis of post-translational modifications. Nat Biotechnol 2003;21: 255-61.
31. Ransohoff DF, Gourlay ML. Sources of bias in specimens for research about molecular markers for cancer. J Clin Oncol 2010;28:698-704.
32. Reiner A, Yekutieli D, Benjamini Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 2003;19:368-75.
33. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003;100: 9440-5.
34. Strimmer K. A unified approach to false discovery rate estimation. BMC Bioinformatics 2008;9:303.
35. Davis MT, Auger PL, Patterson SD. Cancer biomarker discovery via low molecular weight serum profiling-are we following circular paths? Clin Chem 2010;56:244-7.
36. Dupuy A, Simon RM. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 2007;99: 147-57.
37. Karp NA, Lilley KS. Design and analysis issues in quantitative proteomics studies. Proteomics 2007;7(Suppl. 1): 42-50.
38. Marengo E, Robotti E, Bobba M et al. Multivariate statistical tools applied to the characterization of the proteomic profiles of two human lymphoma cell lines by two-dimensional gel electrophoresis. Electrophoresis 2006;27:484-94.
39. Garcia GG, Berger SB, Sadighi Akha AA, Miller RA. Age-associated changes in glycosylation of CD43 and CD45 on mouse CD4 T cells. Eur J Immunol 2005;35: 622-31.
40. Havenaar EC, Axford JS, Brinkman-van der Linden EC et al. Severe rheumatoid arthritis prohibits the pregnancy-induced decrease in alpha3-fucosylation of alpha1-acid glycoprotein. Glycoconj J 1998;15: 723-9.
41. Morgan R, Gao G, Pawling J et al. N-acetylglucosaminyltransferase V (Mgat5)-mediated N-glycosylation negatively regulates Th1 cytokine production by T cells. J Immunol 2004;173:7200-8.
42. Lim SY, Raftery MJ, Goyette J et al. Oxidative modifications of S100 proteins: functional regulation by redox. J Leukoc Biol 2009;86:577-87.
43. Borges CR, Rehder DS, Jarvis JW et al. Full-length characterization of proteins in human populations. Clin Chem 2010;56:202-11.
44. Lange V, Picotti P, Domon B, Aebersold R. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol 2008;4:222.
45. Schiess R, Wollscheid B, Aebersold R. Targeted proteomic strategy for clinical biomarker discovery. Mol Oncol 2009;3:33-44.
46. Pan S, Aebersold R, Chen R et al. Mass spectrometry based targeted protein quantification: methods and applications. J Proteome Res 2009;8:787-97.
47. Kuzyk MA, Smith D, Yang J et al. Multiple reaction monitoring-based, multiplexed, absolute quantitation of proteins in human plasma. Mol Cell Proteomics 2009;8: 1860-77.
48. Keshishian H, Addona T, Burgess M et al. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics 2007;6: 2212-29.
49. Jenkins RE, Kitteringham NR, Hunter CL et al. Relative and absolute quantitative expression profiling of cytochromes P450 using isotope-coded affinity tags. Proteomics 2006; 6:1934-47.
50. Kuhn E, Wu J, Karl J et al. Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labeled peptide standards. Proteomics 2004;4: 1175-86.
51. Liao H, Wu J, Kuhn E et al. Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. Arthritis Rheum 2004;50:3792-803.
52. MacBeath G, Schreiber SL. Printing proteins as microarrays for high-throughput function determination. Science 2000;289:1760-3.
53. Zhu H, Bilgin M, Bangham R et al. Global analysis of protein activities using proteome chips. Science 2001;293: 2101-5.
54. Quintana FJ, Farez MF, Viglietta V et al. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci USA 2008;105:18889-94.
55. Quintana FJ, Hagedorn PH, Elizur G et al. Functional immunomics: microarray analysis of IgG autoantibody repertoires predicts the future response of mice to induced diabetes. Proc Natl Acad Sci USA 2004; 101(Suppl. 2):14615-21.
56. Hueber W, Kidd BA, Tomooka BH et al. Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum 2005;52:2645-55.
57. Hueber W, Tomooka BH, Batliwalla F et al. Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis. Arthritis Res Ther 2009;11:R76.
58. Fattal I, Shental N, Mevorach D et al. An antibody profile of systemic lupus erythematosus detected by antigen microarray. Immunology 2010;130:337-43.
59. Li QZ, Xie C, Wu T et al. Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays. J Clin Invest 2005;115: 3428-39.
60. Somers K, Govarts C, Stinissen P, Somers V. Multiplexing approaches for autoantibody profiling in multiple sclerosis. Autoimmun Rev 2009;8:573-9.
61. Song Q, Liu G, Hu S et al. Novel autoimmune hepatitis-specific autoantigens identified using protein microarray technology. J Proteome Res 2010;9: 30-9.
62. Robinson WH, DiGennaro C, Hueber W et al. Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med 2002;8:295-301.
63. Robinson WH, Fontoura P, Lee BJ et al. Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol 2003;21: 1033-9.
64. Ramachandran N, Hainsworth E, Bhullar B et al. Self-assembling protein microarrays. Science 2004;305: 86-90.
65. Ramachandran N, Raphael JV, Hainsworth E et al. Next-generation high-density self-assembling functional protein arrays. Nat Methods 2008;5:535-8.
66. Wright C, Sibani S, Trudgian D et al. Detection of multiple autoantibodies in patients with ankylosing spondylitis using nucleic acid programmable protein arrays. Mol Cell Proteomics Advance Access published 1 February 2010, doi:10.1074/mcp.M900384-MCP200.
67. Borges CR, Jarvis JW, Oran PE et al. Population studies of intact vitamin D binding protein by affinity capture ESI-TOF-MS. J Biomol Tech 2008;19:167-76.
68. Duncan MW, Aebersold R, Caprioli RM. The pros and cons of peptide-centric proteomics. Nat Biotechnol 2010; 28:659-64.
69. Borges CR, Jarvis JW, Oran PE, Nelson RW. Population studies of vitamin D binding PROTEIN microheterogeneity by mass spectrometry lead to characterization of its genotype-dependent O-glycosylation patterns. J Proteome Res 2008;7:4143-53.
70. Long L, Li R, Li Y et al. Pattern-based diagnosis and screening of differentially expressed serum proteins for rheumatoid arthritis by proteomic fingerprinting. Rheumatol Int 2011;31:1069-74.
71. Dai Y, Hu C, Wang L et al. Serum peptidome patterns of human systemic lupus erythematosus based on magnetic bead separation and MALDI-TOF mass spectrometry analysis. Scand J Rheumatol 2010;39:240-6.
72. Reid JD, Holmes DT, Mason DR et al. Towards the development of an immuno MALDI (iMALDI) mass spectrometry assay for the diagnosis of hypertension. J Am Soc Mass Spectrom 2010;21:1680-6.
73. Rehder DS, Nelson RW, Borges CR. Glycosylation status of vitamin D binding protein in cancer patients. Protein Sci 2009;18:2036-42.
74. Weiss NG, Jarvis JW, Nelson RW, Hayes MA. Examining serum amyloid P component microheterogeneity using capillary isoelectric focusing and MALDI-MS. Proteomics 2011;11:106-13.
75. de Seny D, Fillet M, Ribbens C et al. Monomeric calgranulins measured by SELDI-TOF mass spectrometry and calprotectin measured by ELISA as biomarkers in arthritis. Clin Chem 2008;54:1066-75.
76. Miyamae T, Malehorn DE, Lemster B et al. Serum protein profile in systemic-onset juvenile idiopathic arthritis differentiates response versus nonresponse to therapy. Arthritis Res Ther 2005;7:R746-55.
77. Brauer HA, Lampe PD, Yasui YY et al. Biochips that sequentially capture and focus antigens for immunoaffinity MALDI-TOF MS: a new tool for biomarker verification. Proteomics 2010;10:3922-7.
78. Anderson NL. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem 2010;56:177-85.
79. Wilson C, Schulz S, Waldman SA. Biomarker development, commercialization, and regulation: individualization of medicine lost in translation. Clin Pharmacol Ther 2007; 81:153-5.
80. Fung ET. A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clin Chem 2010;56:327-9.